Gilead Sciences beats Q1 2026 earnings expectations with $6.96 billion in revenue and $2.03 adjusted EPS. The company projects a full-year loss driven by $11.5 billion in acquisition and research charges.
Gilead Sciences reported Q1 2026 revenue of $6.96 billion and adjusted earnings per share of $2.03, both exceeding analyst estimates. The company maintains its full-year Veklury revenue guidance of $600 million but expects a 2026 loss due to $11.5 billion in research and development charges and acquisition costs.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Intuit to lay off 3,000+ employees, refocus on AI
Intuit to lay off over 3,000 employees to refocus on AI
Bank of England's Bailey warns UK food price controls unsustainable
Bank of England Governor Andrew Bailey says UK food price controls are not sustainable long-term, after reports of Treasury asking supermarkets to cap essential product costs.
US imports of Venezuelan oil reach highest level since 2018.
US imports of Venezuelan oil reach highest level since 2018.
Russia cuts forecast for gas exports to key markets, lowers price for China - document
Russia cuts forecast for gas exports to key markets, including China, and lowers gas price for China - document
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.